Typically, tumor whole cell vaccines contain a wide range of tumor-associated antigens, epitopes rich in CD8 T cells, CD4 helper T cells, and can present MHC class I and II restricted antigens simultaneously, promoting a comprehensive and effective anti-tumor response and generating long-lasting memory T cells. Here, CD4 is linked to neoplasm.